Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years with Most Not Receiving Treatment for 4 Years: Care-MS I and Ii Extension Study

Jihad Said Inshasi, Mohammed Al Jumah, Raed Alroughani, D Alasdair S Compston, Massimo Filippi, Gavin Giovannoni, Gavin Giovannoni, Eva Havrdova, Bassem Yamout, David H Margolin, Karthinathan Thangavelu